Globus Medical, Inc. $GMED Shares Sold by Truist Financial Corp

Truist Financial Corp lowered its position in Globus Medical, Inc. (NYSE:GMED) by 51.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 53,034 shares of the medical device company’s stock after selling 56,425 shares during the quarter. Truist Financial Corp’s holdings in Globus Medical were worth $4,630,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Strs Ohio lifted its holdings in Globus Medical by 33.5% in the 4th quarter. Strs Ohio now owns 85,386 shares of the medical device company’s stock worth $7,455,000 after buying an additional 21,405 shares in the last quarter. Artemis Investment Management LLP lifted its holdings in Globus Medical by 43.7% in the 4th quarter. Artemis Investment Management LLP now owns 738,595 shares of the medical device company’s stock worth $64,487,000 after buying an additional 224,587 shares in the last quarter. Horizon Investments LLC acquired a new position in Globus Medical in the 4th quarter worth $5,752,000. New York State Teachers Retirement System lifted its holdings in Globus Medical by 10.5% in the 4th quarter. New York State Teachers Retirement System now owns 96,951 shares of the medical device company’s stock worth $8,465,000 after buying an additional 9,236 shares in the last quarter. Finally, Precision Wealth Strategies LLC acquired a new position in Globus Medical in the 4th quarter worth $547,000. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Stock Performance

Shares of Globus Medical stock opened at $77.81 on Monday. The firm has a market cap of $10.52 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 1.71 and a beta of 1.00. The firm’s 50-day simple moving average is $89.86 and its 200-day simple moving average is $86.65. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insider Buying and Selling at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 18.38% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title
• Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title
• Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title
• Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title

Analyst Ratings Changes

GMED has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Truist Financial set a $115.00 price objective on shares of Globus Medical in a report on Wednesday, February 25th. Wells Fargo & Company cut their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Finally, Needham & Company LLC upped their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $106.36.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.